Pineapple, Inc.

Pineapple, Inc. operates as a portfolio management company in the cannabis sector. The company operates a portfolio of assets that offers operational management, technology, IP licensing, and cannabis property rental services, as well as owns equity in cannabis retail and production facilities. It also provides capital to its canna-business clients; leases properties to canna-businesses; and offers consulting and technologies to develop, enhance, or expand existing and newly formed infrastructures. The company was incorporated in 1983 and is headquartered in Los Angeles, California.

Pineapple, Inc. trades as PNPL on OTC. The company is classified in Healthcare / Medical - Pharmaceuticals and reports in USD.

The current profile places the business in Medical - Pharmaceuticals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $420,000 of revenue and -$1.41M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Pineapple, Inc. can be compared against peers such as Cellbxhealth PLC, Blum Holdings, Inc., Comprehensive Healthcare Systems, Inc., HealthWarehouse.com, Inc., Inhibitor Therapeutics, Inc., LianBio.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.90M, beta of 3.44, and return on equity of +45.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PNPL currently shows total debt of $8.02M and beta of 3.44. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://pineappleinc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.